We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

GALDERMA GROUP AG (GALDY)

21.68

0.00

(0.00%)

At close: March 17 at 4:00:00 PM EDT

Key Events

Loading Chart for GALDY

Previous Close 0.00
Open 19.82
Bid 20.88 x 27000
Ask 21.27 x --
Day's Range 19.82 - 20.32
52 Week Range 15.51 - 27.20
Volume 249
Avg. Volume 10,965
Market Cap (intraday) 25.735B
Beta (5Y Monthly) --
PE Ratio (TTM) 114.11
EPS (TTM) 0.19
Earnings Date Mar 6, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 26.24

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

www.galderma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Sector

Drug Manufacturers - Specialty & Generic

Industry

Galderma's Differin is helping destigmatize acne care with first in category Roblox experience

Galderma's Differin is helping destigmatize acne care with first in category Roblox experience

Galderma Group AG (XSWX:GALD) Full Year 2024 Earnings Call Highlights: Record Sales and ...

Galderma Shares Slide on Expected Hit From Investments

Galderma Shares Slide on Expected Hit From Investments

Galderma to discuss U.S. tariffs with retailers, sees "moving target"

Galderma to discuss U.S. tariffs with retailers, sees "moving target"

Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

Trailing total returns as of 3/17/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD .

YTD Return

GALDY

0.00%

MSCI WORLD

0.55%

1-Year Return

GALDY

30.21%

MSCI WORLD

9.98%

3-Year Return

GALDY

30.21%

MSCI WORLD

25.96%

5-Year Return

GALDY

30.21%

MSCI WORLD

117.21%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

GALDERMA GROUP AG

21.68

0.00%

Mkt Cap 25.735B

Industry Drug Manufacturers—Specialty & Generic

Glenmark Pharmaceuticals Limited

1,440.35

+0.66%

Mkt Cap INR 406.449B

Industry Drug Manufacturers—Specialty & Generic

Sandoz Group AG

44.94

-7.78%

Mkt Cap 19.96B

Industry Drug Manufacturers—Specialty & Generic

Glenmark Pharmaceuticals Limited

1,446.75

+1.20%

Mkt Cap INR 408.642B

Industry Drug Manufacturers—Specialty & Generic

H. Lundbeck A/S

39.64

+0.92%

Mkt Cap DKK 37.923B

Industry Drug Manufacturers—Specialty & Generic

Avant Brands Inc.

0.7050

+3.51%

Mkt Cap 7.495M

Industry Drug Manufacturers—Specialty & Generic

Biofrontera Inc.

1.0100

+8.60%

Mkt Cap 8.963M

Industry Drug Manufacturers—Specialty & Generic

Sandoz Group AG

37.65

+1.59%

Mkt Cap CHF 16.216B

Industry Drug Manufacturers—Specialty & Generic

Sandoz Group AG

42.78

-0.16%

Mkt Cap 18.425B

Industry Drug Manufacturers—Specialty & Generic

13.59

+2.95%

Mkt Cap 864.145M

Industry Drug Manufacturers—Specialty & Generic

Takeda Pharmaceutical Company Limited

15.18

+1.13%

Mkt Cap 47.963B

Industry Drug Manufacturers—Specialty & Generic

Valuation Measures

    Annual 

As of 3/17/2025

Market Cap

24.66B
Enterprise Value

26.96B
Trailing P/E

111.75
Forward P/E

39.53
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

5.81
Price/Book (mrq)

3.30
Enterprise Value/Revenue

6.07
Enterprise Value/EBITDA

28.12

Financial Highlights

Profitability and Income Statement

Profit Margin

5.20%
Return on Assets (ttm)

3.34%
Return on Equity (ttm)

3.51%
Revenue (ttm)

4.44B
Net Income Avi to Common (ttm)

231M
Diluted EPS (ttm)

0.19

Balance Sheet and Cash Flow

Total Cash (mrq)

457M
Total Debt/Equity (mrq)

35.42%
Levered Free Cash Flow (ttm)

131.38M

Revenue vs. Earnings

Revenue 1.15B

Earnings --

Q2'24

Q3'24

Q4'24

0

200M

400M

600M

800M

1B

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Analyst Price Targets

26.24

26.24 Average

21.68 Current

26.24 High

GALDY does not have Company Insights

GDERF GALDERMA GROUP AG

108.65

0.00%

BESVF BE Semiconductor Industries N.V.

117.76

0.00%

NBFJF Nippon Building Fund Inc.

816.80

0.00%

GBERF Geberit AG

641.80

0.00%

CHLSY Chocoladefabriken Lindt & Sprüngli AG

13.69

+2.39%

BLBLF Bilibili Inc.

21.88

0.00%

HGMCF Harmony Gold Mining Company Limited

12.00

0.00%

BSQKZ Block, Inc.

55.00

0.00%

HSNGF Hang Seng Bank Limited

13.39

0.00%

BZLYF Beazley plc

11.65

0.00%

AMFPF Amplifon S.p.A.

22.00

0.00%

ASRRF ASR NEDERLAND NV

50.49

0.00%

ARRPY Aeroports de Paris SA

12.30

0.00%

BMBLF Brambles Limited

12.51

0.00%

MEDOF Medios AG

50.00

0.00%

DVCMY Davide Campari-Milano N.V.

6.38

-0.31%